Garodia Chemicals Limited Q1FY27 Loss Widens to ₹10.39 Lakh

Garodia Chemicals Limited reported a net loss of ₹10.39 lakh in Q1FY27, compared with a ₹5.81 lakh loss a year earlier, as the company recorded no revenue from operations and total expenses increased 78.8% year-on-year.

What did Garodia Chemicals report for Q1FY27?

Garodia Chemicals reported standalone unaudited results for the quarter ended June 30, 2026, showing a net loss of ₹10.39 lakh. The loss was higher than ₹5.81 lakh in the corresponding quarter of the previous financial year. Revenue from operations was nil in both periods.

The company’s quarterly results show that the absence of operating revenue continued for the third consecutive disclosed quarter. With no sales recorded, the rise in expenditure translated directly into a larger operating loss and net loss for the June quarter.

Total expenses stood at ₹10.39 lakh in Q1FY27, against ₹5.81 lakh in Q1FY26. Other expenses were the main component, increasing to ₹9.64 lakh from ₹5.06 lakh. Employee benefits expense remained unchanged at ₹0.75 lakh.

The quarterly data published for Garodia Chemicals also records sales of nil across the periods from June 2023 through June 2026. Operating profit for June 2026 was a loss of ₹0.10 crore, compared with an operating loss of ₹0.06 crore in the June 2025 quarter.

Why did the quarterly loss widen?

The Q1FY27 loss widened because expenses increased while the company did not report any operating or other income for the quarter. Total expenses rose by 78.8% year-on-year, led by the increase in other expenses.

Other expenses of ₹9.64 lakh represented most of the total quarterly cost of ₹10.39 lakh. The available results do not provide a more detailed break-up of the items included under other expenses. Employee benefits expense was stable, indicating that the year-on-year increase came from non-employee cost items.

The lack of sales means there was no operating income available to absorb recurring or administrative costs. This has been reflected consistently in the company’s quarterly profit and loss table, where nil sales are accompanied by operating losses in every disclosed quarter from June 2023 to June 2026.

How does the June quarter compare with FY26?

The June-quarter loss followed a profitable FY26 for Garodia Chemicals, but the full-year profit was primarily linked to other income rather than revenue from operations. For the year ended March 31, 2026, the company reported net profit of ₹3.9167 crore, compared with a net loss of ₹0.21 crore in FY25.

Other income for FY26 was ₹4.0588 crore, while total expenses were ₹0.1421 crore. The company’s March 2026 quarter, however, reported no sales and a net loss of ₹0.02 crore. The contrast between the full-year profit and the recurring quarterly operating losses is important when reviewing the reported FY26 outcome.

In Q2FY26, Garodia Chemicals reported profit after tax of ₹4.0249 crore, with total revenue of ₹4.0588 crore derived entirely from other income. The company reported no revenue from operations in that quarter as well. This indicates that the FY26 profit was not supported by a resumption of product sales or regular operating income.

Past disclosures also referred to going-concern issues, management’s decision to cease business, and uncertainty around certain balances and liabilities. These points were flagged in the auditor-related disclosures accompanying the Q2 and Q3 FY26 results, providing context for the continued lack of operating revenue in later periods.

What corporate actions accompanied the Q1FY27 results?

The board approved the unaudited June-quarter financial results on August 14, 2026, along with the appointment of Mrs. Sarita Subhash Salunkhe as an additional non-executive, non-independent director. Her appointment was subject to shareholder approval at the Annual General Meeting scheduled for September 30, 2026.

Laxmikant Kabra and Co LLP conducted the limited review of the standalone unaudited results. The firm issued an unmodified opinion on the June-quarter results prepared under Ind AS 34, according to the company’s disclosure.

Garodia Chemicals subsequently informed BSE Limited that its board would meet on November 6, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026. The trading window for designated persons and their immediate relatives was closed from October 1, 2026, and will remain closed until 48 hours after the results are declared.

The scheduled September-quarter board meeting is the next formal financial disclosure identified in the available information. It will provide the next reported update on expenses, any operating revenue, and the company’s financial position after the June quarter.

What does the result mean for investors and operations?

For investors, the June-quarter result highlights that Garodia Chemicals continued to report nil operating revenue and a quarterly loss despite the FY26 net profit. The distinction matters because the FY26 profit was mainly supported by other income of ₹4.0588 crore, while the latest quarterly result did not show such income.

The available financial data does not establish an operating recovery. Sales have remained nil in the disclosed quarterly series, and expenses have continued to create losses in the absence of revenue. The company’s earlier disclosures regarding cessation of business and going-concern uncertainty add further context to its operating position.

The share price shown in the supplied data was ₹10.67, unchanged. No trading-volume data, market-capitalisation figure, or investor reaction was provided. Therefore, the available information supports an assessment of the reported financial position but does not establish a market response to the June-quarter announcement.

Conclusion

Garodia Chemicals Limited’s Q1FY27 result showed a ₹10.39 lakh loss, wider than the ₹5.81 lakh loss reported a year earlier, with no revenue from operations and higher other expenses. While FY26 ended with a ₹3.9167 crore net profit, the reported figures show that this outcome was primarily driven by other income rather than recurring sales.

The next item to watch is the board’s consideration of unaudited results for the quarter and half year ended September 30, 2026, scheduled for November 6, 2026. That disclosure is expected to clarify whether operating revenue remains nil, how expenses have moved, and whether the company provides any updated information on its business status.